scholarly journals Waning of IgG, total and neutralizing antibodies 6 months post-vaccination with BNT162b2 in healthcare workers

2021 ◽  
Author(s):  
Jean-Louis Bayart ◽  
Jonathan Douxfils ◽  
Constant Gillot ◽  
Clara David ◽  
François Mullier ◽  
...  
Keyword(s):  
Neutralizing Antibodies ◽  
Healthcare Workers ◽  
Booster Dose ◽  
Vaccination Strategy ◽  
Humoral Response ◽  
Clinical Effectiveness ◽  
Igg Antibodies ◽  
Post Vaccination ◽  
Antibody Decline ◽  
Potential Use

Abstract Data about the duration of humoral response following COVID-19 vaccines are mandatory to establish appropriate population vaccination strategy. This study reports on the antibody decline observed in a population of COVID-19 naïve and COVID-19 positive individuals having received the two dose regimen of the BNT162b2 vaccine. Six months after vaccination, a significant antibody decline was observed in both COVID-19 naïve and positive individuals. The estimated half-life of total and IgG antibodies differs and ranges from several months for total antibodies to only several weeks for IgG antibodies, explaining the significant proportions of participants with non-detectable levels of neutralizing antibodies at 6 months. Whether this decrease correlates with an equivalent drop in the clinical effectiveness against the virus will require appropriate clinical studies. Nevertheless, these data are already important to support the decision-making on the potential use of a booster dose.

scholarly journals Waning of IgG, Total and Neutralizing Antibodies 6 Months Post-Vaccination with BNT162b2 in Healthcare Workers

Vaccines ◽  
2021 ◽  
Vol 9 (10) ◽  
pp. 1092
Author(s):  
Jean-Louis Bayart ◽  
Jonathan Douxfils ◽  
Constant Gillot ◽  
Clara David ◽  
François Mullier ◽  
...  
Keyword(s):  
Half Life ◽  
Neutralizing Antibodies ◽  
Healthcare Workers ◽  
Healthcare Professionals ◽  
Humoral Response ◽  
Clinical Effectiveness ◽  
Antibody Assay ◽  
Post Vaccination ◽  
Antibody Decline

Data about the long-term duration of antibodies after SARS-CoV-2 vaccination are still scarce and are important to design vaccination strategies. In this study, 231 healthcare professionals received the two-dose regimen of BNT162b2. Of these, 158 were seronegative and 73 were seropositive at baseline. Samples were collected at several time points. The neutralizing antibodies (NAbs) and antibodies against the nucleocapsid and the spike protein of SARS-CoV-2 were measured. At day 180, a significant antibody decline was observed in seronegative (−55.4% with total antibody assay; −89.6% with IgG assay) and seropositive individuals (−74.8% with total antibody assay; −79.4% with IgG assay). The estimated half-life of IgG from the peak humoral response was 21 days (95% CI: 13–65) in seronegative and 53 days (95% CI: 40–79) in seropositive individuals. The estimated half-life of total antibodies was longer and ranged from 68 days (95% CI: 54–90) to 114 days (95% CI: 87–167) in seropositive and seronegative individuals, respectively. The decline of NAbs was more pronounced (−98.6%) and around 45% of the subjects tested were negative at day 180. Whether this decrease correlates with an equivalent drop in the clinical effectiveness against the virus would require appropriate clinical studies.

scholarly journals Rapid detection of neutralizing antibodies to SARS-CoV-2 variants in post-vaccination sera

2021 ◽  
Author(s):  
Kei Miyakawa ◽  
Sundararaj Stanleyraj Jeremiah ◽  
Hideaki Kato ◽  
Yutaro Yamaoka ◽  
Hirofumi Go ◽  
...  
Keyword(s):  
Neutralizing Antibodies ◽  
Large Scale ◽  
Small Sample Size ◽  
Vaccination Strategy ◽  
Humoral Response ◽  
Small Sample ◽  
Post Vaccination ◽  
Infected People ◽  
Prototype Virus ◽  
Wide Testing

The uncontrolled spread of the COVID-19 pandemic has led to the emergence of different SARS-CoV-2 variants across the globe. The ongoing global vaccination strategy to curtail the COVID-19 juggernaut, is threatened by the rapidly spreading Variants of Concern (VOC) and other regional mutants, which are less responsive to neutralization by infection or vaccine derived antibodies. We have previously developed the hiVNT system which detects SARS-CoV-2 neutralizing antibodies in sera in less than three hours. In this study, we modify the hiVNT for rapid qualitative screening of neutralizing antibodies (nAb) to multiple variants of concern (VOC) of SARS-CoV-2, and assess the neutralizing efficacy of the BNT162b2 mRNA vaccine on seven epidemiologically relevant SARS-CoV-2 variants. Here we show that the BNT162b2 mRNA vaccine can activate humoral immunity against the major SARS-CoV-2 mutants that are currently in circulation. Albeit a small sample size, we observed that one dose of vaccine was sufficient to elicit a protective humoral response in previously infected people. Using a panel of seven SARS-CoV-2 variants and a single prototype virus, our modified hiVNT would be useful for large-scale community wide testing to detect protective immunity that may confer vaccine/immune passport in the ongoing COVID-19 pandemic.

scholarly journals Comprehensive assessment of humoral response after Pfizer BNT162b2 mRNA Covid-19 vaccination: a three-case series

2021 ◽  
Author(s):  
Elisa Danese ◽  
Martina Montagnana ◽  
Gian Luca Salvagno ◽  
Matteo Gelati ◽  
Denise Peserico ◽  
...  
Keyword(s):  
Immune Response ◽  
Neutralizing Antibodies ◽  
Healthcare Workers ◽  
Protein Concentration ◽  
Venous Blood ◽  
Case Series ◽  
Vaccine Dose ◽  
Humoral Response ◽  
Post Vaccination ◽  
Humoral Immune

Background. Since universal vaccination is a pillar against coronavirus disease 2019 (COVID-19), monitoring anti-SARS-CoV-2 neutralizing antibodies is essential for deciphering post-vaccination immune response. Methods. Three healthcare workers received 30 μg BNT162b2 mRNA Covid-19 Vaccine, followed by a second identical dose, 21 days afterwards. Venous blood was drawn at baseline and at serial intervals, up to 63 days afterwards, for assessing total immunoglobulins (Ig) anti-RBD (receptor binding domain), IgG anti-S1/S2, IgG anti-RBD, IgM anti-RBD, IgM anti-N/S1 and IgA anti-S1. Results. All subjects were SARS-CoV-2 seronegative at baseline. Total Ig anti-RBD, IgG anti-S1/S2 and IgG anti-RBD levels increased between 91-368 folds until 21 days after the first vaccine dose, then reached a plateau. The levels raised further after the second dose (by ~30-, ~8- and ~8-fold, respectively), peaking at day 35, but then slightly declining and stabilizing ~50 days after the first dose. IgA anti-S1 levels increased between 7-11 days after the first dose, slightly declined before the second dose, after which levels augmented by ~24-fold from baseline. The anti-RBD and anti-N/S1 IgM kinetics were similar to that of anti-S1 IgA, though displaying substantially weaker increases and modest peaks, only 4 to 7-fold higher than baseline. Highly significant inter-correlation was noted between total Ig anti-RBD, anti-S1/S2 and anti-RBD IgG (all r=0.99), whilst other anti-SARS-CoV-2 antibodies displayed lower, though still significant, correlations. Serum spike protein concentration was undetectable at all time points. Conclusions. BNT162b2 mRNA vaccination generates a robust humoral immune response, especially involving IgG and IgA, magnified by the second vaccine dose.

scholarly journals Study of neutralizing [anti-RBD] antibody responses induced by COVID-19 vaccines in healthcare professionals in a diagnostic centre of Central India

2021 ◽  
Vol 8 (2) ◽  
pp. 75-78
Author(s):  
Ranjana Hawaldar ◽  
Sadhna Sodani ◽  
Varsha Sodani ◽  
R K Sodani
Keyword(s):  
Neutralizing Antibodies ◽  
Booster Dose ◽  
Healthcare Professionals ◽  
Adaptive Immune Response ◽  
Vaccine Dose ◽  
Central India ◽  
Antibody Responses ◽  
Igg Antibodies ◽  
Contributing Factors ◽  
Post Vaccination

India began administration of COVID-19 vaccines on 16 January 2021. Reliable quantification of the antibody response to SARS-CoV-2 vaccination is highly relevant for identifying possible vaccine efficiency and estimating the time of protection. Healthcare Professionals were the first group of beneficiaries of this vaccine. we aimed to evaluate the neutralizing [anti-RBD] antibody responses induced by COVID-19 vaccines after first and booster dose in healthcare professionals 69 healthcare professionals [HCPs] Were enrolled for the evaluation study. The COVISHILED vaccine developed by AstraZeneca, University of Oxford and manufactured and distributed in India by the Serum Institute of India was administered to all the participants. All participants were evaluated to detect levels neutralizing IgG antibodies on three occasions:,first pre vaccination level, second on approximately 27th day and third on 68th day from baselining & first vaccine dose to assess change in levels of neutralizing IgG antibodies post vaccination On approximately 27 day from first vaccine dose, 45 out of 51 participants in investigational cohort were sero-converted for anti-RBD antibodies. Out of 6 participants that were yet to sero-convert 5 demonstrated increased level of neutralizing [anti-RBD] antibodies but did not cross the reactivity threshold to confirm presence of neutralizing [anti-RBD] antibodies. On approximately 68 day from second vaccine dose, 49 out of 51 participants in investigational cohort were sero-converted for anti-RBD antibodies. 4 additional participants sero-converted post booster dose .96.0% produced neutralizing [anti-RBD] antibodies post vaccination. 2 participants continued to remain non-reactive.This is the first data of serological responses to COVID-19 vaccines in IBD patients with detailed analysis of antibodies RBD/spike proteins represented amongst HCPs from central India. Study also demonstrates that the level of neutralizing antibodies produced may vary due to several contributing factors and hence periodic monitoring of neutralizing antibodies before and post vaccination can help evaluate adaptive immune response induced by specific individual in response to vaccine administered.

Antibody titers decline 3-month post-vaccination with BNT612b2

2021 ◽  
Author(s):  
Julien Favresse ◽  
Jean-Louis Bayart ◽  
François Mullier ◽  
Marc Elsen ◽  
Christine Eucher ◽  
...  
Keyword(s):  
Half Life ◽  
Healthcare Professionals ◽  
Vaccine Dose ◽  
Vaccination Strategy ◽  
Humoral Response ◽  
Post Vaccination ◽  
Peak Response ◽  
Antibody Titers ◽  
Antibody Decline ◽  
Kinetics Of

Abstract Introduction: Several studies reported on the humoral response in subjects having received theBNT162b2 mRNA COVID-19 vaccine. However, data on the kinetics of antibodies 3 months postvaccinationare currently lacking and are important to drive the future vaccination strategy.Methods: The CRO-VAX HCP study is an ongoing multicenter, prospective and interventional studydesigned to assess the antibody response in a population of healthcare professionals who had receivedtwo doses of the BNT162b2 mRNA COVID-19 vaccine. Two-hundred individuals underwent a blooddrawn within 2 days before the first vaccine dose. One-hundred and forty-two persons (71%) werecategorized as seronegative at baseline while 58 (29%) were seropositive. Samples were then collectedafter 14, 28, 42, 56, and 90 days. Antibodies against the SARS-CoV-2 nucleocapsid and the receptorbinding domain of the S1 subunit of the spike protein were measured in all individuals at different timepoints.Results: Using a one-compartment kinetics model, the time to maximum concentration was estimatedat 36 ± 3 days after the first dose and the estimated half-life of antibodies was 55 days (95% CI: 37-107days) in seronegative participants. In seropositive participants, the time to maximum concentrationwas estimated at 24 ± 4 days and the estimated half-life was 80 days (95% CI: 46-303 days). Theantibody response was higher in seropositive compared to seronegative participants.Conclusion: In both seropositive and seronegative subjects, a significant antibody decline wasobserved at 3 months compared to the peak response. Nevertheless, the humoral response remainedrobust in all participants.

scholarly journals Rapid detection of neutralizing antibodies to SARS-CoV-2 variants in post-vaccination sera

2021 ◽  
Author(s):  
Kei Miyakawa ◽  
Jeremiah Sundararaj Stanleyraj ◽  
Hideaki Kato ◽  
Yutaro Yamaoka ◽  
Hirofumi Go ◽  
...  
Keyword(s):  
Neutralizing Antibodies ◽  
Large Scale ◽  
Small Sample Size ◽  
Vaccination Strategy ◽  
Humoral Response ◽  
Small Sample ◽  
Post Vaccination ◽  
Infected People ◽  
Prototype Virus ◽  
Wide Testing

Abstract The uncontrolled spread of the COVID-19 pandemic has led to the emergence of different SARS-CoV-2 variants across the globe. The ongoing global vaccination strategy to curtail the COVID-19 juggernaut, is threatened by the rapidly spreading Variants of Concern (VOC) and other regional mutants, which are less responsive to neutralization by infection or vaccine derived antibodies. We have previously developed the hiVNT system which detects SARS-CoV-2 neutralizing antibodies in sera in less than three hours. In this study, we modify the hiVNT for rapid qualitative screening of neutralizing antibodies (nAb) to multiple VOC of SARS-CoV-2, and assess the neutralizing efficacy of the BNT162b2 mRNA vaccine on seven epidemiologically relevant SARS-CoV-2 variants. Here we show that the BNT162b2 mRNA vaccine can activate humoral immunity against the major SARS-CoV-2 mutants that are currently in circulation. Albeit a small sample size, we observed that one dose of vaccine was sufficient to elicit a protective humoral response in previously infected people. Using a panel of seven SARS-CoV-2 variants and a single prototype virus, our modified hiVNT would be useful for large-scale community wide testing to detect protective immunity that may confer vaccine/immune passport in the ongoing COVID-19 pandemic.

scholarly journals Comprehensive assessment of humoral response after Pfizer BNT162b2 mRNA Covid-19 vaccination: a three-case series

2021 ◽  
Vol 0 (0) ◽  
Author(s):  
Elisa Danese ◽  
Martina Montagnana ◽  
Gian Luca Salvagno ◽  
Denise Peserico ◽  
Laura Pighi ◽  
...  
Keyword(s):  
Immune Response ◽  
Neutralizing Antibodies ◽  
Healthcare Workers ◽  
Protein Concentration ◽  
Venous Blood ◽  
Case Series ◽  
Vaccine Dose ◽  
Humoral Response ◽  
Post Vaccination ◽  
Humoral Immune

Abstract Objectives Since universal vaccination is a pillar against coronavirus disease 2019 (COVID-19), monitoring anti-SARS-CoV-2 neutralizing antibodies is essential for deciphering post-vaccination immune response. Methods Three healthcare workers received 30 μg BNT162b2 mRNA Covid-19 Pfizer Vaccine, followed by a second identical dose, 21 days afterwards. Venous blood was drawn at baseline and at serial intervals, up to 63 days afterwards, for assessing total immunoglobulins (Ig) anti-RBD (receptor binding domain), anti-S1/S2 and anti-RBD IgG, anti-RBD and anti-N/S1 IgM, and anti-S1 IgA. Results All subjects were SARS-CoV-2 seronegative at baseline. Total Ig anti-RBD, anti-S1/S2 and anti-RBD IgG levels increased between 91 and 368 folds until 21 days after the first vaccine dose, then reached a plateau. The levels raised further after the second dose (by ∼30-, ∼8- and ∼8-fold, respectively), peaking at day 35, but then slightly declining and stabilizing ∼50 days after the first vaccine dose. Anti-S1 IgA levels increased between 7 and 11 days after the first dose, slightly declined before the second dose, after which levels augmented by ∼24-fold from baseline. The anti-RBD and anti-N/S1 IgM kinetics were similar to that of anti-S1 IgA, though displaying substantially weaker increases and modest peaks, only 4- to 7-fold higher than baseline. Highly significant inter-correlation was noted between total Ig anti-RBD, anti-S1/S2 and anti-RBD IgG (all r=0.99), whilst other anti-SARS-CoV-2 antibodies displayed lower, though still significant, correlations. Serum spike protein concentration was undetectable at all-time points. Conclusions BNT162b2 mRNA vaccination generates a robust humoral immune response, especially involving anti-SARS-Cov-2 IgG and IgA, magnified by the second vaccine dose.

scholarly journals Rapid seroconversion and persistent functional IgG antibodies in severe COVID-19 patients correlates with an IL-12p70 and IL-33 signature

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Ariel Munitz ◽  
L. Edry-Botzer ◽  
M. Itan ◽  
R. Tur-Kaspa ◽  
D. Dicker ◽  
...  
Keyword(s):  
Nucleocapsid Protein ◽  
Neutralizing Antibodies ◽  
Host Response ◽  
Humoral Response ◽  
Rapid Onset ◽  
Response Analysis ◽  
Receptor Binding Domain ◽  
Igg Antibodies ◽  
Viral Receptor ◽  
Iga Antibodies

AbstractDespite ongoing efforts to characterize the host response toward SARS-CoV-2, a major gap in our knowledge still exists regarding the magnitude and duration of the humoral response. Analysis of the antibody response in mild versus moderate/severe patients, using our new developed quantitative electrochemiluminescent assay for detecting IgM/IgA/IgG antibodies toward SARS-CoV-2 antigens, revealed a rapid onset of IgG/IgA antibodies, specifically in moderate/severe patients. IgM antibodies against the viral receptor binding domain, but not against nucleocapsid protein, were detected at early stages of the disease. Furthermore, we observed a marked reduction in IgM/IgA antibodies over-time. Adapting our assay for ACE2 binding-competition, demonstrated that the presence of potentially neutralizing antibodies is corelated with IgG/IgA. Finally, analysis of the cytokine profile in COVID-19 patients revealed unique correlation of an IL-12p70/IL33 and IgG seroconversion, which correlated with disease severity. In summary, our comprehensive analysis has major implications on the understanding and monitoring of SARS-CoV-2 infections.

scholarly journals Characterization of the significant decline in humoral immune response six months post-SARS-CoV-2 mRNA vaccination: A systematic review

2021 ◽  
Author(s):  
Kin Israel Notarte ◽  
Israel Guerrero-Arguero ◽  
Jacqueline Veronica Velasco ◽  
Abbygail Therese Ver ◽  
Maria Helena Santos de Oliveira ◽  
...  
Keyword(s):  
Humoral Response ◽  
Serum Levels ◽  
Related Factors ◽  
Post Vaccination ◽  
Humoral Immune ◽  
Antibody Titers ◽  
Waning Immunity ◽  
Antibody Class ◽  
Antibody Decline ◽  
Primary Cycle

Accumulating evidence shows a progressive decline in the efficacy of coronavirus disease 2019 (COVID-19) mRNA vaccines such as Pfizer-BioNTech (mRNA BNT161b2) and Moderna (mRNA-1273) in preventing breakthrough infections due to diminishing humoral immunity over time. Thus, this review characterizes the kinetics of anti-SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) antibodies after the second dose of a primary cycle of COVID-19 mRNA vaccination. A systematic search of literature was performed and a total of 18 studies (N=15,980) were identified and reviewed. The percent difference of means of reported antibody titers were then calculated to determine the decline in humoral response after the peak levels post-vaccination. Findings revealed that the peak humoral response was reached at 21-28 days after the second dose, after which serum levels progressively diminished at 4-6 months post-vaccination. Additionally, results showed that regardless of age, sex, serostatus and presence of comorbidities, longitudinal data reporting antibody measurement exhibited a decline of both anti-receptor binding domain (RBD) IgG and anti-spike IgG, ranging from 94-95% at 90-180 days and 55-85% at 140-160 days, respectively, after the peak antibody response. This suggests that the rate of antibody decline may be independent of patient-related factors and peak antibody titers but mainly a function of time and antibody class/molecular target. Hence, this study highlights the necessity of more efficient vaccination strategies to provide booster administration in attenuating the effects of waning immunity, especially in the appearance of new variants of concerns (VoCs).

scholarly journals Seroprevalence of SARS-CoV-2 IgG Antibodies After the Second BNT162b2 mRNA Vaccine in Japanese Kidney Transplant Recipients

2021 ◽  
Author(s):  
Tomoko Hamaya ◽  
Shingo Hatakeyama ◽  
Tohru Yoneyama ◽  
Yuki Tobisawa ◽  
Hirotake Kodama ◽  
...  
Keyword(s):  
Mycophenolate Mofetil ◽  
Kidney Transplant ◽  
Neutralizing Antibodies ◽  
Humoral Response ◽  
Healthy Controls ◽  
Transplant Recipients ◽  
Igg Antibodies ◽  
Kidney Transplant Recipients ◽  
Univariate Logistic Regression Analysis ◽  
Antibody Titers

Abstract We aimed to evaluate the rate of anti–SARS-CoV-2 IgG seropositivity and investigated factors associated with seropositivity after the second SARS-CoV-2 mRNA vaccination in kidney transplant (KT) recipients. This retrospective study conducted between June 2021 and November 2021 included 106 KT recipients and 127 healthy controls who received the second dose of the BNT162b2 mRNA vaccine at least seven days before the measurement of antibody titers. The titers of immunoglobulin G (IgG) antibodies against the receptor-binding domain of SARS-CoV-2 spike (S) protein were determined. Seropositivity was defined as an anti–SARS-CoV-2 IgG level of ≥15 units/mL, which was considered as the presence of sufficient neutralizing antibodies. The median ages and the seroprevalence rates of the healthy controls and KT recipients were 68 and 56 years and 98% and 22%, respectively. Univariate logistic regression analysis revealed that age >53 years, rituximab use, mycophenolate mofetil use, and KT vintage <7 years were negatively associated with anti–SARS-CoV-2 IgG seropositivity in KT recipients. Humoral response after the second BNT162b2 mRNA vaccine was greatly hindered by immunosuppression therapy in KT recipients. Older age, rituximab use, mycophenolate mofetil use, and KT vintage may play key roles in seroconversion.

Sign in / Sign up

Export Citation Format

Share Document